Scandion Oncology - Positive outlook for SCO-101
Scandion Oncology is approaching a major inflection point as results from the Phase II CORIST trial of the company’s lead asset, SCO-101, in metastatic colorectal cancer, are expected in Q322. In addition, top-line data from the extended Phase Ib PANTAX study in pancreatic cancer are expected in H123 (previously Q322). In H122, R&D related expenses rose to DKK33.0m, from DKK20.4m in H121, as patient enrolment continued for CORIST and PANTAX. In July 2022, Scandion completed a rights issue, which we estimate will result in a net cash injection of c SEK58m (c DKK41m). At end H122, management reported a cash position of DKK72.7m, however, including net proceeds from the equity raise, we estimate this figure to have risen to c DKK113.7m. At the current burn rate (H122: DKK32.4m), and considering estimated clinical activities, we anticipate the company is funded into FY24, past key readouts in FY22 and FY23. We value Scandion Oncology at SEK609.5m or SEK15.0 per share (previously SEK586.5m or SEK14.4 per share).Scandion Oncology A/S. Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.